Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
Conditions
- Recurrent Squamous Cell Lung Carcinoma
- Stage IV Squamous Cell Lung Carcinoma
Interventions
- OTHER: Laboratory Biomarker Analysis
- DRUG: Taselisib
Sponsor
SWOG Cancer Research Network
Collaborators